Adverum Biotechnologies (ADVM) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Strong Phase 2 Results and Favorable Safety Profile Justify Buy Rating for Adverum Biotechnologies
TipRanksJul 22 08:16 ET · Ratings
More Than $10M Bet On Appian? Check Out These 3 Stocks Insiders Are Buying
BenzingaJul 19 13:17 ET
Express News | Chardan Capital Maintains Buy on Adverum Biotechnologies, Adjusts Price Target To $40 ((Reverse Stock Split 1:10))
BenzingaJul 18 17:12 ET
Adverum Biotechnologies Analyst Ratings
BenzingaJul 18 17:01 ET
Chardan Research Adjusts Adverum Biotechnologies' PT to $40 From $4, Maintains Buy Rating
MT NewswiresJul 18 08:16 ET
Truist Financial Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Announces Target Price $23
Moomoo NewsJul 18 07:31 ET · Ratings

Comments

Jaguar8

Jul 17 02:57

NEWS

$Adverum Biotechnologies(ADVM.US)$
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
Adverum Biotechnologies (Nasdaq: ADVM) presented positive 26-week interim results from the LUNA Phase 2 trial of Ixo-vec for wet AMD at the 2024 ASRS Annual Meeting. Key findings include:
1. The 6E10 dose with local prophylaxis was selected for Phase 3 trials.
2. 76% of 6E10 patients were injection-fr...

2

Jaguar8

Apr 25 15:10

$Adverum Biotechnologies(ADVM.US)$
NEWS
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

Trytosaveabit

Feb 8 06:05

Update

$Adverum Biotechnologies(ADVM.US)$ Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...

1

2

QianmengYu

Feb 5 14:44

Sold half at 1.8 but chart look good

$Adverum Biotechnologies(ADVM.US)$ 2 insiders buy 200k cash in private placement, settlement Feb 8 the data release day. Lol, simple insider trading. Are they stupid? Anyway, there won’t be surprise for the data release, should be safe pass.
Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...

1

BadDuck74

Feb 5 07:38

$Adverum Biotechnologies(ADVM.US)$Adverum Biotechnologies Has Agreed To Sell Approximately 106.25M Shares In A Private Placement At $1.20/Share With Gross Proceeds Of Approximately $127.5M; Pro Forma Cash And Investments Expected To Fund Current Operating Plan Into Late 2025

1

ADVM Adverum Biotechnologies

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target